Abstract:With high prevalence and substantial mortality, metabolic dysfunction-associated steatotic liver disease and chronic obstructive pulmonary disease (COPD) are significant public health concerns. Utilizing a large, population-based dataset from the National Health and Nutrition Examination Survey, our study probes the relationship between COPD prevalence and hepatic steatosis and fibrosis, as measured by Vibration-Controlled Transient Elastography. We analyzed data from 693 individuals with COPD and 7229 without. Through weighted multivariate logistic regression analysis, a restricted cubic spline curve, and threshold effect analysis, we investigated the correlation between the severity of hepatic steatosis and fibrosis and the presence of COPD. Our findings revealed a positive correlation between the controlled attenuation parameter (CAP) and COPD prevalence [OR = 1.03 (95% CI 1.01, 1.05)], even after multivariate adjustment. Furthermore, we observed a U-shaped association between CAP and COPD, where the inflection point, CAP value of 264.85 dB/m, corresponded to the lowest COPD prevalence. Our study emphasizes a substantial and complex link between hepatic steatosis and COPD. These findings urge healthcare professionals to factor liver health into COPD management and prompt further exploration into the underlying mechanisms. This could pave the way for the development of improved prevention and treatment strategies.

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to explore the relationship between hepatic steatosis and hepatic fibrosis and chronic obstructive pulmonary disease (COPD). Specifically, the study utilized a large - scale population data set from the National Health and Nutrition Examination Survey (NHANES), evaluated the degree of hepatic steatosis and fibrosis through vibration - controlled transient elastography (VCTE), and analyzed the association between these indicators and the prevalence of COPD. ### Research Background - **COPD**: Chronic obstructive pulmonary disease is a common respiratory disease with high morbidity and mortality worldwide. - **MASLD**: Metabolic - dysfunction - associated steatotic liver disease (MASLD), formerly known as non - alcoholic fatty liver disease (NAFLD), is a global health problem, affecting approximately 30% of the global population. - **Comorbidity relationship**: COPD patients are often accompanied by other metabolic diseases, such as MASLD, and these comorbidities will increase the severity and mortality risk of COPD. ### Research Objectives - **Primary objective**: To explore the relationship between the degree of hepatic steatosis and fibrosis and the prevalence of COPD. - **Methods**: Use VCTE technology to evaluate hepatic steatosis and fibrosis, and explore this relationship through multivariate logistic regression analysis, restricted cubic spline curves and threshold effect analysis. ### Main Findings - **Relationship between CAP and COPD**: In the case of unadjusted covariates, for every 10 dB/m increase in CAP value, the prevalence of COPD increases by 3% [OR = 1.03 (95% CI 1.02, 1.05)]. Even in the fully adjusted model, this relationship remains significant [OR = 1.03 (95% CI 1.01, 1.05)]. - **U - shaped relationship**: There is a U - shaped relationship between CAP value and the prevalence of COPD. When the CAP value is 264.85 dB/m, the prevalence of COPD is the lowest. Below this point, hepatic steatosis is negatively correlated with COPD; above this point, it is positively correlated. - **Relationship between LSM and COPD**: In the case of unadjusted covariates, for every 10 kPa increase in LSM value, the prevalence of COPD increases by 18% [OR = 1.18 (95% CI 1.05, 1.32)]. But in the partially and fully adjusted models, this relationship becomes non - significant [OR = 1.10 (95% CI 0.97, 1.22)]. ### Discussion - **Mechanism**: There may be multiple shared risk factors between COPD and hepatic steatosis, such as obesity, insulin resistance and systemic inflammation. These factors may play a role in the progression of both through inflammatory cytokines and adipokines. - **Obesity paradox**: The inflection point of CAP value observed in the study may reflect the complex relationship between body composition and the progression of chronic diseases. A moderate level of body fat may provide a protective effect in chronic diseases, which is in line with the concept of the obesity paradox. ### Conclusion - **Importance**: The study emphasizes the significant and complex association between hepatic steatosis and COPD, suggesting that liver health should be considered in COPD management. - **Future directions**: Future research should further explore the mechanisms driving this association in order to develop more effective prevention and treatment strategies.

Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults

Controlled Attenuation Parameter by VCTE for Steatosis Assessment in Health Check Public with Reference to MRI-PDFF.

Usefulness Of Controlled Attenuation Parameter And Liver Stiffness Measurement For Detecting Increased Arterial Stiffness In Asymptomatic Populations In China

Prevalence of Hepatic Steatosis, Fibrosis and Associated Factors in Chronic Hepatitis B

Low Liver Density Is Linked to Cardiovascular Comorbidity in COPD: An ECLIPSE Cohort Analysis

Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease

Metabolic dysfunction-associated steatotic liver disease-related hepatic fibrosis increases risk of insulin resistance, type 2 diabetes, and chronic kidney disease

The Impact of Lung Function on Extra-Pulmonary Diseases and All-Cause Mortality in US Adult Population with and Without COPD

Association between cardiometabolic index and hepatic steatosis and liver fibrosis: a population-based study

Correlation between the metabolic score for visceral fat and chronic obstructive pulmonary disease among middle-aged and elderly American population

Prognostic Effects of Liver Fibrosis and Steatosis Determined Using Transient Elastography in Patients with Chronic Hepatitis B or C

Epidemiological and transcriptome data identify association between iron overload and metabolic dysfunction-associated steatotic liver disease and hepatic fibrosis

Cardiometabolic Index and chronic obstructive pulmonary disease: A population-based cross-sectional study

Air pollution associate with advanced hepatic fibrosis among patients with chronic liver disease

Non-linear association between long-term air pollution exposure and risk of metabolic dysfunction-associated steatotic liver disease

Association between chronic obstructive pulmonary disease and serum lipid levels: a meta-analysis

Association Between Different Types of Physical Activity and Hepatic Steatosis and Liver Fibrosis

The association between pan-immune-inflammation value and chronic obstructive pulmonary disease: data from NHANES 1999–2018

Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China.

IDDF2023-ABS-0072 High Prevalence of Hepatic Steatosis and Fibrosis among Patients with Type 2 Diabetes Mellitus: a Prospective Community-Based Study

Association between metabolic dysfunction-associated steatotic liver disease and pulmonary function: a population-based and two-sample mendelian randomization study